ClinicalTrials.gg
CompletedNCT07844070Updated Nov 19, 2026

A Study of Disease Modifying Therapy Use in Women With Multiple Sclerosis Before, During, and After Pregnancy

An observational study in Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

Updated Nov 19, 2026Now CompletedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,607
Ages
18 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Multiple Sclerosis by Novartis — 9 open to participants now, 23 under way, 6 of them phase 3. Multiple Sclerosis · Novartis.

Enrollment
6th of 41
2,607 · median 312
Started
2026
with 3 others
Observational
41 of 106
7 open now
Registered
106th of 106
by date

Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 6th largest by enrollment of the 41 observational ones that give a count, is one of 4 that started in 2026, is one of 41 observational ones, and was the 106th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

9 of the 106 studies in Multiple Sclerosis by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 49 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Multiple Sclerosis by Novartis, or all of them as a file.
02

Study summary

This study aims to assess the real-world patterns of disease modifying therapy (DMT) use before, during, and after pregnancy in women with multiple sclerosis (MS). The study will use a pooled closed claims database containing closed payer medical and pharmacy claims data for patients in the United States (US).

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
  • Pregnancy
  • Disease-Modifying Therapy
  • Peripartum
  • Postpartum Period
  • Treatment Patterns
  • Womens Health
  • Real-World Evidence
  • Healthcare Claims Data
  • Retrospective Cohort Study
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women with a confirmed diagnosis of MS who had a live birth any time from August 20, 2020 to September 30, 2024 (identification period) or 6 months prior to end of study period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥1 claim with a diagnosis or procedure code for live birth during the patient identification period (index date).

    o Note: For patients with more than one pregnancy in the patient identification period, all eligible pregnancies will be included.

  • Female sex recorded on enrollment record overlapping with index date.
  • Aged between 18 and 49 years old at index date.
  • ≥2 claims with an MS diagnosis (International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code G35) ≥30 days apart in the pre-conception or pregnancy periods.
  • Continuous healthcare plan enrollment from ≥6 months prior to the conception date to ≥6 months following the index date.

Exclusion criteria

Exclusion criteria:

  • Pregnancies involving multiples, subject to data availability.
  • in pre-conception, pregnancy, or post-delivery periods.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,607 participants (actual)
Patient registry
No

Groups and cohorts

  • MS Group

    Women with MS who experienced at least one live birth between August 20, 2020 and September 30, 2024.

06

What researchers measure

Primary outcomes

  1. Proportion of Patients With ≥1 DMT Claim During the Pre-Conception Period

    Time frame: 6 months prior to the estimated conception date

  2. Proportion of Patients With ≥1 DMT Claim During Pregnancy

    Time frame: Day 0 to 90 (Trimester 1), Day 91 to 181 (Trimester 2), Day 182 up to and including the day before the delivery date (Trimester 3), and Day 0 up to approximately Day 280 (pregnancy period)

  3. Proportion of Patients With ≥1 DMT Claim During the Post-Delivery Period

    Time frame: Post-delivery 0 to 1.5 months, 1.5 to 3 months, 4 to 6 months, >6 months, up to approximately 4.5 years

Secondary outcomes

  1. Proportion of Patients by Demographic and Clinical Characteristics

    Demographics and clinical characteristics include: * Age group * Race * Geographical region * Type of healthcare insurance coverage * Payer type * Year of index date * Mode of delivery * Use of fertility treatments * Deyo-Charlson Comorbidity Index (DCCI) category (0, 1-2, ≥3) * Psychological Diagnosis Group (PDG) * Comorbidities * MS-related symptoms and secondary conditions * MS disability (no disability symptoms, mild, moderate, severe)

    Time frame: 6 months prior to the estimated conception date

  2. DCCI Score

    DCCI is an adaptation of the Charlson Comorbidity Index that uses diagnosis codes from administrative or claims data to quantify a patient's burden of comorbid conditions. It assigns weighted scores to a set of medical conditions based on their impact on mortality risk. DCCI scores start at 0, with higher scores indicating a greater number of and/or severe comorbid conditions.

    Time frame: 6 months prior to the estimated conception date

  3. Number of PDG Mental Health Disorders

    PDG captures a list of mental health disorders a patient may have. The following are the list of PDGs: * Adult personality disorders * Anxiety disorders * Behavioral syndromes * Childhood and adolescent psychiatric syndromes * Intellectual disabilities * Psychiatric disorders with known physiological causes * Mood disorders * Pervasive disorders * Schizophrenia * Substance use

    Time frame: 6 months prior to the estimated conception date

  4. Age

    Time frame: 6 months prior to the estimated conception date

  5. Proportion of Patients by DMT Use During the Pre-Conception Period

    Proportion of patients by type of DMT used during pre-conception reported by DMT class and generic name.

    Time frame: 6 months prior to the estimated conception date

  6. Proportion of Patients by DMT Use During Pregnancy

    Proportion of patients by type of DMT used during pregnancy reported by DMT class and generic name.

    Time frame: Day 0 to 90 (Trimester 1), Day 91 to 181 (Trimester 2), Day 182 up to and including the day before the delivery date (Trimester 3), and Day 0 up to approximately Day 280 (pregnancy period)

  7. Proportion of Patients by DMT Use During the Post-Delivery Period

    Proportion of patients by type of DMT used post-delivery reported by DMT class and generic name.

    Time frame: Post-delivery 0 to 1.5 months, 1.5 to 3 months, 4 to 6 months, >6 months, up to approximately 4.5 years

  8. Proportion of Patients by Sequences of DMTs Used During the Pre-Conception Period

    Time frame: 6 months prior to the estimated conception date

  9. Proportion of Patients by Sequences of DMTs Used During Pregnancy

    Time frame: Day 0 to 90 (Trimester 1), Day 91 to 181 (Trimester 2), Day 182 up to and including the day before the delivery date (Trimester 3), and Day 0 up to approximately Day 280 (pregnancy period)

  10. Proportion of Patients by Sequences of DMTs Used During the Post-Delivery Period

    Time frame: Post-delivery 0 to 1.5 months, 1.5 to 3 months, 4 to 6 months, >6 months, up to approximately 4.5 years

  11. Time to First Observed DMT Claim in the Post-Delivery Period

    Time to first observed DMT claim in the post-delivery period among (a) patients without a DMT claim in the pre-conception or pregnancy periods (i.e., time to DMT initiation) and (b) patients with a DMT claim in the pre-conception and/or pregnancy periods (i.e., time to DMT continuation).

    Time frame: Post-delivery 0 to 1.5 months, 1.5 to 3 months, 4 to 6 months, >6 months, up to approximately 4.5 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2026 to primary completion in Oct 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 28, 2026
StartActual
Mar 6, 2026
Primary completionActual
Oct 30, 2026
CompletionActual
Oct 30, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 19, 2026
Registered
First appeared on the registry
Sep 28, 2026
Show all 2 updates
  1. Nov 19, 2026
    Active, not recruiting→Completed
    + 1 other change: date precision
  2. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07844070
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Mar 6, 2026
Primary completion
Oct 30, 2026
Completion
Oct 30, 2026
Last update
Nov 19, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion